Adjuvant therapies are often approved based on composite, surrogate endpoints with high costs per event averted
A total of 11 approvals were included in the analysis. During analyzed period, all approvals were based on a surrogate endpoint with no studies demonstrating, to date, an overall survival benefit. The median cost per event averted of drugs in the adjuvant setting was 1 610 000 USD (range, 820 000 USD to 2 640 000 USD). The median cost of a complete adjuvant treatment was 158 000 USD per patient.